BMO Capital analyst Evan David Seigerman maintains Merck & Co (NYSE:MRK) with a Outperform and lowers the price target from $150 to $136.
BMO Capital Maintains Outperform on Merck & Co, Lowers Price Target to $136
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.